Single-cell exome sequencing reveals polyclonal seeding and TRPS1 mutations in colon cancer metastasis.

Signal Transduct Target Ther

Department of Hepatobiliary Surgery, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Published: September 2024

AI Article Synopsis

  • Liver metastasis is the leading cause of death in colon cancer patients, and identifying gene mutations involved in this process may provide new treatment targets.
  • Researchers conducted a detailed analysis of cancer cells from a stage IV colon cancer patient, revealing that both liver and lymphatic metastases originated from the primary tumor but with greater genetic diversity than the primary tumor itself.
  • The study highlights a specific mutation in the TRPS1 gene that increases cancer cell invasion and suggests that liver metastases often arise from multiple tumor cell clusters rather than a single cell, indicating a more complex mechanism of metastasis progression.

Article Abstract

Liver metastasis remains the primary cause of mortality in patients with colon cancer. Identifying specific driver gene mutations that contribute to metastasis may offer viable therapeutic targets. To explore clonal evolution and genetic heterogeneity within the metastasis, we conducted single-cell exome sequencing on 150 single cells isolated from the primary tumor, liver metastasis, and lymphatic metastasis from a stage IV colon cancer patient. The genetic landscape of the tumor samples revealed that both lymphatic and liver metastases originated from the same region of the primary tumor. Notably, the liver metastasis was derived directly from the primary tumor, bypassing the lymph nodes. Comparative analysis of the sequencing data for individual cell pairs within different tumors demonstrated that the genetic heterogeneity of both liver and lymphatic metastases was also greater than that of the primary tumor. This finding indicates that liver and lymphatic metastases arose from clusters of circulating tumor cell (CTC) of a polyclonal origin, rather than from a single cell from the primary tumor. Single-cell transcriptome analysis suggested that higher EMT score and CNV scores were associated with more polyclonal metastasis. Additionally, a mutation in the TRPS1 (Transcriptional repressor GATA binding 1) gene, TRPS1 R544Q, was enriched in the single cells from the liver metastasis. The mutation significantly increased CRC invasion and migration both in vitro and in vivo through the TRPS1/ZEB1 axis. Further TRPS1 mutations were detected in additional colon cancer cases, correlating with advanced-stage disease and inferior prognosis. These results reveal polyclonal seeding and TRPS1 mutation as potential mechanisms driving the development of liver metastases in colon cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417107PMC
http://dx.doi.org/10.1038/s41392-024-01960-8DOI Listing

Publication Analysis

Top Keywords

colon cancer
20
primary tumor
20
liver metastasis
16
metastasis
9
single-cell exome
8
exome sequencing
8
polyclonal seeding
8
seeding trps1
8
trps1 mutations
8
liver
8

Similar Publications

Introduction: Colonoscopies are medical procedures used to identify colon abnormalities and remove polyps to decrease the incidence of colorectal cancer. Prior to this exam, patients must undergo bowel preparation to ensure proper cleansing of the colon and maximize outcomes (e.g.

View Article and Find Full Text PDF

Background: The metal oxide nanoparticles possess unique properties such as biological compatibility, superior reactivity, and capacity to develop reactive oxygen species, due to this they have drawn significant interest in cancer treatment. The various MONPs such as cerium oxide, Copper oxide, Iron oxide, Titanium dioxide, and Zinc oxide have been investigated for several types of cancers including brain, breast, cervical, colon, leukemia, liver, lung, melanoma, ovarian, and prostate cancers. However, traditional physiochemical synthetic methods for MONPs commonly include toxic materials, a major concern that raises questions regarding their biocompatibility and safety.

View Article and Find Full Text PDF

Hesperidin inhibits colon cancer progression by downregulating SLC5A1 to suppress EGFR phosphorylation.

J Cancer

January 2025

Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, China.

Hesperidin, an active constituent of traditional Chinese medicine, Chenpi, exhibits anticancer properties across different cancers. This study aimed to clarify the efficacy of Hesperidin against tumors and its mechanisms of action in colon cancer. : We assessed the efficacy of Hesperidin on human colon cancer cells (HCT-116 and DLD-1) and normal colonic epithelial cells (NCM460).

View Article and Find Full Text PDF

Background: The narrative review aims to explore CRC pathogenesis by deciphering genetic-environmental interactions, analyzing the tumor microenvironment's role, and assessing treatment responses. These objectives seek to enhance clinical decision-making and improve CRC patient care through a comprehensive understanding of the disease.

Methods: A narrative review from 2019 to 2024 on colorectal cancer (CRC) pathogenesis and treatment strategies was conducted.

View Article and Find Full Text PDF

Background: Amyloidosis combined with lung cancer is a rare occurrence. To date, there are no reported cases of amyloid light-chain(AL) amyloidosis solely affecting the colon combined with pulmonary adenocarcinoma.

Case Summary: Here, we describe a case of a 66-year-old woman who presented with recurrent abdominal pain and was eventually diagnosed with AL amyloidosis with colon involvement and pulmonary adenocarcinoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!